We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals
AGIO

178 hedge funds and large institutions have $2.69B invested in Agios Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 66 increasing their positions, 58 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 22

14% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 58

4% more funds holding

Funds holding: 171 → 178 (+7)

1.21% more ownership

Funds ownership: 95.18% → 96.38% (+1.2%)

13% less capital invested

Capital invested by funds: $3.07B → $2.69B (-$388M)

33% less call options, than puts

Call options by funds: $10.2M | Put options by funds: $15.1M

80% less funds holding in top 10

Funds holding in top 10: 5 → 1 (-4)

Holders
178
Holders Change
+7
Holders Change %
+4.09%
% of All Funds
4.04%
Holding in Top 10
1
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-80%
% of All Funds
0.02%
New
30
Increased
66
Reduced
58
Closed
22
Calls
$10.2M
Puts
$15.1M
Net Calls
-$4.96M
Net Calls Change
-$9.09M

Top Buyers

1
UBS AM
UBS AM
Illinois
+$19.7M
2
PAMU
Pictet Asset Management (UK)
United Kingdom
+$14.7M
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$14M
4
PI
Putnam Investments
Massachusetts
+$13.3M
5
First Trust Advisors
First Trust Advisors
Illinois
+$10.7M

Top Sellers

1
Capital International Investors
Capital International Investors
California
-$20.5M
2
CI
Capital International
California
-$13.2M
3
QIM
Quantitative Investment Management
Virginia
-$10.3M
4
Invesco
Invesco
Georgia
-$8.69M
5
CWAM
Columbia Wanger Asset Management
Illinois
-$8.12M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$418M +$3.21M +51,064 +0.7%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$390M +$3.51M +55,810 +0.8%
Vanguard Group
3
Vanguard Group
Pennsylvania
$189M +$751K +11,929 +0.4%
Capital International Investors
4
Capital International Investors
California
$161M -$20.5M -325,029 -10%
BlackRock
5
BlackRock
New York
$161M -$3.71M -58,909 -2%
BB
6
BB Biotech
Switzerland
$156M -$1.89M -30,000 -1%
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$104M +$4.89M +77,710 +4%
ClearBridge Investments
8
ClearBridge Investments
New York
$87.4M -$31.3K -497 -0%
State Street
9
State Street
Massachusetts
$76.8M +$5.47M +86,918 +7%
Balyasny Asset Management
10
Balyasny Asset Management
Illinois
$64.6M +$10.3M +164,111 +17%
Goldman Sachs
11
Goldman Sachs
New York
$59.8M +$7.2M +114,401 +12%
Invesco
12
Invesco
Georgia
$48.5M -$8.69M -138,038 -14%
First Trust Advisors
13
First Trust Advisors
Illinois
$46.5M +$10.7M +169,331 +26%
CWAM
14
Columbia Wanger Asset Management
Illinois
$43.5M -$8.12M -129,026 -15%
CGT
15
Capital Guardian Trust
California
$37.9M -$4.19M -66,625 -9%
Capital World Investors
16
Capital World Investors
California
$37.9M – – –
Alkeon Capital Management
17
Alkeon Capital Management
New York
$29.3M +$3.45M +54,858 +12%
AG
18
Artal Group
Luxembourg
$28.6M +$3.15M +50,000 +11%
Janus Henderson Group
19
Janus Henderson Group
United Kingdom
$27.7M +$6.08M +96,703 +25%
Lord, Abbett & Co
20
Lord, Abbett & Co
New Jersey
$21.6M -$7.08M -112,541 -23%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$21.1M +$256K +4,073 +1%
UBS AM
22
UBS AM
Illinois
$19.7M +$19.7M +312,878 +965%
Norges Bank
23
Norges Bank
Norway
$18.1M – – –
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
$18M +$14M +223,106 +245%
Brown Advisory
25
Brown Advisory
Maryland
$17.4M +$842K +13,386 +5%
1
2 3 4 5

AGIO Hedge Fund Activity: Q4 2017 in Review

178 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q4 2017, worth a combined $2.69B — down 13% from $3.07B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new AGIO positions and 22 closed out — a net gain of 8 holders — while 66 added to existing stakes and 58 trimmed.

The largest buyer was UBS AM, adding an estimated $19.7M. The largest seller was Capital International Investors, cutting an estimated $20.5M.

  • 178 institutional investors held Agios Pharmaceuticals (AGIO) as of Q4 2017, up from 171 in Q3 2017.
  • Funds reported $2.69B of Agios Pharmaceuticals stock for Q4 2017, down 13% quarter-over-quarter.
  • 30 funds opened new Agios Pharmaceuticals positions in Q4 2017 and 22 closed out, a net change of +8 holders.
  • The largest Agios Pharmaceuticals buyer in Q4 2017 was UBS AM, an estimated $19.7M added.
  • The largest Agios Pharmaceuticals seller in Q4 2017 was Capital International Investors, an estimated $20.5M sold.

Based on aggregated 13F filings for Q4 2017.